Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCIQ is a subunit-selective potentiator of NMDA receptors containing the GluN2C (formally NR2C) or GluN2D (formally NR2D) subunit. Increases channel opening efficiency and enhances NMDA receptor responses.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
CIQ is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 467.94 |
Formula | C26H26ClNO5 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 486427-17-2 |
PubChem ID | 4231127 |
InChI Key | VYMILMYEENZHAR-UHFFFAOYSA-N |
Smiles | O=C(C3=CC(Cl)=CC=C3)N2C(COC4=CC=C(OC)C=C4)C1=CC(OC)=C(OC)C=C1CC2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 46.79 | 100 |
The following data is based on the product molecular weight 467.94. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.14 mL | 10.69 mL | 21.37 mL |
5 mM | 0.43 mL | 2.14 mL | 4.27 mL |
10 mM | 0.21 mL | 1.07 mL | 2.14 mL |
50 mM | 0.04 mL | 0.21 mL | 0.43 mL |
References are publications that support the biological activity of the product.
Mullasseril et al (2010) A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat.Commun. 1 1 PMID: 20975674
If you know of a relevant reference for CIQ, please let us know.
Keywords: CIQ, CIQ supplier, NMDA, receptors, potentiators, NR2C, NR2D, subunits, enhances, opening, efficiency, GluN2C, GluN2D, Receptors, 4105, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for CIQ include:
Kashima and Grueter (2017) Toll-like receptor 4 deficiency alters nucleus accumbens synaptic physiology and drug reward behavior. Proc Natl Acad Sci U S A. 114 8865 PMID: 28760987
Hedegaard et al (2012) Molecular pharmacology of human NMDA receptors. Neurochem Int 61 601 PMID: 22197913
Do you know of a great paper that uses CIQ from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review CIQ and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.